Genprex, Inc. (NASDAQ:GNPX – Get Free Report) was down 3.9% during trading on Wednesday . The stock traded as low as $1.93 and last traded at $1.96. Approximately 35,531 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 94,474 shares. The stock had previously closed at $2.04.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Genprex in a report on Wednesday, May 15th.
Check Out Our Latest Stock Report on Genprex
Genprex Trading Down 4.3 %
Genprex (NASDAQ:GNPX – Get Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($3.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($1.15). On average, equities analysts predict that Genprex, Inc. will post -5.7 earnings per share for the current fiscal year.
About Genprex
Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.
Further Reading
- Five stocks we like better than Genprex
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Options Trading – Understanding Strike Price
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Best Stocks Under $10.00
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.
